Using Long-Acting Injectable Buprenorphine as a Means to Discontinue Medication for Addiction Treatment of Opiate Use Disorder

Presented by Jeff Ripperda, MD, Family Physician, Co-Founder of Shawnee Health's Substance Use Disorder Program

This case series describes the experiences of sixteen patients with a history of opiate use disorder who had been stable on buprenorphine treatment, but who expressed a desire to discontinue medication for addiction therapy.  These patients received variable dosages and durations of long-acting injectable buprenorphine.  At least ten of the patients successfully discontinued medication for addiction treatment.

Learning objectives:
After the presentation, attendees will be able to:
Identify patients who are potential candidates for discontinuation of medication for addiction treatment.
Identify a potential medication protocol for cessation of medication for addiction treatment.

This CME activity meets Illinois state requirements for safe opioid prescribing and federal training requirements for opioid safety.

The AAFP has reviewed Using Long-Acting Injectable Buprenorphine as a Means to Discontinue Medication for Addiction Treatment of Opiate Use Disorder and deemed it acceptable for up to 1.00 Live AAFP Prescribed credit(s). Term of Approval is from 09/30/2026 to 09/30/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.